Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theratechnologies have signed a supply, distribution and licensing agreement with Actelion Pharmaceuticals Canada.
Subscribe to our email newsletter
The contract provides Actelion with the exclusive commercialization rights to tesamorelin in Canada.
As per the agreement, Actelion will be responsible for all ongoing regulatory and future commercialization activities in connection with tesamorelin in Canada.
Theratechnologies will manufacture and supply of tesamorelin to Actelion, who will purchase tesamorelin at a predetermined transfer price.
Theratechnologies president and CEO John-Michel Huss said with a sales force already in place, Actelion will be in a position to effectively market tesamorelin, once approved.